Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
02:50pm, Tuesday, 14'th Jan 2025
REGN announces business updates at the J.P. Morgan Healthcare Conference.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pu
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc.(REGN) Shareholders
12:00pm, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)
11:30am, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:15am, Tuesday, 14'th Jan 2025
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders
11:00am, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors in NASDAQ: REGN shares should contact the Shareholders Foundation at mail@shareholdersfound
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky
07:25am, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regenero
NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceu
Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
07:08pm, Monday, 13'th Jan 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 5:15 PM ET Company Participants Leonard Schleifer - Board Co-Chair, Co-Founder, Presi
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
